ArticleEBioMedicine2025
Global emergence of Carbapenem-resistant Hypervirulent Klebsiella pneumoniae driven by an IncFII
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- Genomic analyses identify nosocomial transmission of ST23 carbapenem-resistant hypervirulentVirulence · 2026Article
- Can we escape from top-priority ESKAPE pathogens?Emerging microbes & infections · 2026Review
- ElevatedEmerging microbes & infections · 2026Article
- Prevalence of fimH and class I, II, and III integron-associated integrase genes among extensively drug-resistant Klebsiella pneumoniae isolates in Isfahan, Iran.Molecular biology reports · 2026Article
- Short-Term Within-Host Genomic Diversity and Clone Turnover of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Factors associated with severity inNew microbes and new infections · 2026Article
- Advances in CRISPR-Cas for Diagnosis and Treatment ofPathogens (Basel, Switzerland) · 2026Review
- Clinical characteristics and 28-day outcomes of sepsis associated with klebsiella pneumoniae carbapenemase-producing Enterobacterales: a single-center retrospective cohort study.BMC infectious diseases · 2026Article
- Emergence and dissemination of extensively drug-resistant ST307Microbial genomics · 2026Article
- Genomic Epidemiology of ESBL and Non-ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Hidden burden of intestinal Klebsiella pneumoniae in Taiwan: insights into pathogenic potentials and genomic diversity.Gut pathogens · 2026Article
- Genomic diversity in the critical priority pathogen Klebsiella pneumoniae: global and regional perspectives.BMC microbiology · 2026Article
- Data-driven spatial-temporal framework for exploring the heterogeneity and temporality of sepsis.Chinese medical journal · 2026Review
- Co-evolution of resistance and virulence inFrontiers in cellular and infection microbiology · 2026Review
- Genomic epidemiology ofFrontiers in microbiology · 2026Article
- Genomic evidence for putative insertion sequence-associated chromosomal integration of aerobactin virulence loci in ST11 carbapenem-resistantFrontiers in microbiology · 2026Article
- Carbapenem-resistant hypervirulentFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundCarbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKp) has been increasingly reported worldwide, posing a severe challenge to public health; however, the mechanisms driving its emergence and global dissemination remain unclear.
methodsWe analysed CR-hvKp strains derived from canonical hvKp backgrounds, and acquired a carbapenemase-encoding gene. These strains were identified from 485 CRKp isolates in the CRACKLE-2 China cohort, 259 CRKp isolates from a multi-centre study, and 67,631 K. pneumoniae genomes available in GenBank. Clinical isolates harbouring the IncFII
findingsAnalysis of clinical CR-hvKp isolates and the 414 genomes from 24 countries available in GenBank identified an IncFII
interpretationThe IncFII
fundingNational Natural Science Foundation of China and National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.